Question · asked by 1 review

Cyclosporin A in orabase (topical) vs Placebo (orabase): Oral ulcers (number, size, healing time)

Population
People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Intervention
Cyclosporin A in orabase (topical)
Comparison
Placebo (orabase)
Outcome
Oral ulcers (number, size, healing time)

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Cyclosporin A in orabase (topical, 70 mg/g) vs Placebo (orabase)
Oral ulcers (number, size, healing time) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;…
Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes
Ergun 1997 (cyclosporin A in orabase vs placebo orabase, 24 patients; high risk of reporting bias): no data were presented; authors reported no clinical improvement in the number, size, and healing time of ulcers for…1 study · 24 participantsGRADE not reported

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Interventions for managing oral ulcers in Behçet's disease
2014 · Cochrane All outcomes
2013-10Not listedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.